From CNV to exome: Integrated genetic testing
Fulgent's Focus and Comprehensive Cancer Panels give the physician the ability to easily select the right test for their patient that is most relevant to their medical care. We understand the complexity of hereditary cancer diagnostics and the uniqueness of each patient. Explore the best option for your patient needs.
New genes added to our preset, focus, and comprehensive panels.
Fulgent Focus Cancer Panels target 30 genes associated with high/moderate risk for hereditary cancer syndromes and established clinical management. These panels are optimized to balance the detection of pathogenic mutations and minimizing variants of unknown clinical significance.
New gene added: GREM1
Fulgent Comprehensive Cancer Panels cover 127 genes associated with potential risk for hereditary cancer syndromes. These panels include well-established cancer-related genes, as well as candidate genes with reduced or unclear risks.
New genes added: CTNNA1, GREM1, NTHL1, SLC45A2
Our Lab is CLIA-certified and CAP accredited and surpasses the standards of diagnostic testing. All specimens are processed at our US laboratory. All data analysis is performed on private US server centers.